drugset / Trial / NCT00290927
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
* To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy. * To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy. * To evaluate the safety of HMR1964.
Timeline
- Start
- 2003-12
- Primary completion
- —
- Completion
- —
Outcome
Met primary endpoint
paper Superiority of glulisine + OAD and glulisine monotherapy vs. OAD only was shown by differences in adjusted mean HbA(1c) change from baseline values of -1.46% (p < 0.0001) and -0.64% (p < 0.0001) respectively. PMID 19614946 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |